EA030745B1 - Комбинация анти-cd20 антитела и селективного ингибитора киназы pi3 - Google Patents

Комбинация анти-cd20 антитела и селективного ингибитора киназы pi3 Download PDF

Info

Publication number
EA030745B1
EA030745B1 EA201590866A EA201590866A EA030745B1 EA 030745 B1 EA030745 B1 EA 030745B1 EA 201590866 A EA201590866 A EA 201590866A EA 201590866 A EA201590866 A EA 201590866A EA 030745 B1 EA030745 B1 EA 030745B1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibody
fluoro
compound
fluorophenyl
amino
Prior art date
Application number
EA201590866A
Other languages
English (en)
Russian (ru)
Other versions
EA201590866A1 (ru
Inventor
Майкл Вейсс
Хари Мискин
Питер Спортелли
Сваруп К.В.С. Ваккаланка
Original Assignee
ТиДжи ТЕРАПЬЮТИКС, ИНК.
Райзен Фармасьютикалз Са
Лаборатуар Франсэ Дю Фраксьоннеме Э Де Биотехнологи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54264181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA030745(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ТиДжи ТЕРАПЬЮТИКС, ИНК., Райзен Фармасьютикалз Са, Лаборатуар Франсэ Дю Фраксьоннеме Э Де Биотехнологи filed Critical ТиДжи ТЕРАПЬЮТИКС, ИНК.
Publication of EA201590866A1 publication Critical patent/EA201590866A1/ru
Publication of EA030745B1 publication Critical patent/EA030745B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201590866A 2012-11-02 2013-11-01 Комбинация анти-cd20 антитела и селективного ингибитора киназы pi3 EA030745B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN4595CH2012 2012-11-02
US201361771812P 2013-03-02 2013-03-02
PCT/US2013/067956 WO2014071125A1 (en) 2012-11-02 2013-11-01 Combination of anti-cd20 antibody and pi3 kinase selective inhibitor

Publications (2)

Publication Number Publication Date
EA201590866A1 EA201590866A1 (ru) 2015-12-30
EA030745B1 true EA030745B1 (ru) 2018-09-28

Family

ID=54264181

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590866A EA030745B1 (ru) 2012-11-02 2013-11-01 Комбинация анти-cd20 антитела и селективного ингибитора киназы pi3

Country Status (22)

Country Link
US (3) US9694071B2 (enExample)
EP (3) EP3756686A1 (enExample)
JP (1) JP6437441B2 (enExample)
KR (2) KR102185175B1 (enExample)
CN (2) CN110269941A (enExample)
AU (3) AU2013337733B2 (enExample)
BR (1) BR112015009879A8 (enExample)
CA (1) CA2890176C (enExample)
CL (1) CL2015001124A1 (enExample)
CY (1) CY1123938T1 (enExample)
DK (1) DK3150256T3 (enExample)
EA (1) EA030745B1 (enExample)
IL (1) IL238564B (enExample)
LT (1) LT3150256T (enExample)
MX (2) MX375325B (enExample)
NZ (1) NZ708249A (enExample)
PL (1) PL3150256T3 (enExample)
RS (1) RS60844B1 (enExample)
SG (2) SG10201704511RA (enExample)
SI (1) SI3150256T1 (enExample)
SM (1) SMT202000543T1 (enExample)
WO (1) WO2014071125A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2240451T3 (da) 2008-01-04 2017-11-20 Intellikine Llc Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
PE20180318A1 (es) 2011-01-10 2018-02-09 Infinity Pharmaceuticals Inc Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
LT2914296T (lt) 2012-11-01 2018-09-25 Infinity Pharmaceuticals, Inc. Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
EP3164506A4 (en) * 2014-07-01 2018-02-28 Mayo Foundation for Medical Education and Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
MX2018010415A (es) 2016-03-18 2018-11-29 Hutchinson Fred Cancer Res Composiciones y metodos para inmunoterapia de grupo de diferenciacion 20 (cd20).
MX2018014577A (es) * 2016-05-27 2019-05-20 Tg Therapeutics Inc Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b.
UA125216C2 (uk) 2016-06-24 2022-02-02 Інфініті Фармасьютікалз, Інк. Комбінована терапія
EP3509634A1 (en) * 2016-09-09 2019-07-17 TG Therapeutics Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en) 2017-03-30 2018-10-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
EP3668507A4 (en) * 2017-08-14 2021-05-12 MEI Pharma, Inc. Combination therapy
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021164789A1 (zh) * 2020-02-21 2021-08-26 南京明德新药研发有限公司 一种吡唑并嘧啶类化合物的晶型及其应用
CN114891005B (zh) * 2022-03-30 2024-01-19 武汉九州钰民医药科技有限公司 一种乌帕利斯对甲苯磺酸盐的制备工艺
IL317240A (en) * 2022-06-01 2025-01-01 Tg Therapeutics Inc Anti-CD20 antibody compositions
US11807689B1 (en) * 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
KR20250125901A (ko) * 2024-02-13 2025-08-22 연세대학교 산학협력단 항-CD20 항체 및 PIKfyve의 억제제를 유효성분으로 포함하는 림프종의 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2000541A1 (en) * 2006-03-07 2008-12-10 Osaka University Humanized anti-cd20 monoclonal antibody
WO2010014595A2 (en) * 2008-07-31 2010-02-04 The Ohio State University Research Foundation Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
WO2014006572A1 (en) * 2012-07-04 2014-01-09 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6190370B1 (en) 1997-07-25 2001-02-20 Arrow International, Inc. Devices, systems and methods for determining proper placement of epidural catheters
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2844455B1 (fr) 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
CN103833854B (zh) 2002-12-16 2017-12-12 健泰科生物技术公司 免疫球蛋白变体及其用途
FR2858235B1 (fr) 2003-07-31 2006-02-17 Lab Francais Du Fractionnement Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs
FR2879204B1 (fr) * 2004-12-15 2007-02-16 Lab Francais Du Fractionnement Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
FR2939314A1 (fr) * 2008-12-04 2010-06-11 Univ Victor Segalen Bordeaux 2 Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales
AU2010224125B2 (en) * 2009-03-12 2015-05-14 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
AP2012006294A0 (en) 2009-11-05 2012-06-30 Rhizen Pharmaceuticals Sa Novel kinase modulators.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2000541A1 (en) * 2006-03-07 2008-12-10 Osaka University Humanized anti-cd20 monoclonal antibody
WO2010014595A2 (en) * 2008-07-31 2010-02-04 The Ohio State University Research Foundation Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders
WO2014006572A1 (en) * 2012-07-04 2014-01-09 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Anonymous: "Reportonbusiness.com: globeinvestor.com", 24 August 2012 (2012-08-24), XP055099249, Retrieved from the Internet: URL:http://www.globeinvestor.com/servlet/WireFeedRedirect?cf=GlobeInvestor/config&vg=BigAdVariableGenerator&date=20120824&archive=infolink&slug=10003004 [retrieved on 2014-01-29], paragraphs [0001], [0004], [0005] *

Also Published As

Publication number Publication date
BR112015009879A2 (enExample) 2014-05-08
EP3756686A1 (en) 2020-12-30
US20200323981A1 (en) 2020-10-15
US20170304441A1 (en) 2017-10-26
IL238564B (en) 2020-11-30
EA201590866A1 (ru) 2015-12-30
EP2914343B1 (en) 2019-03-06
CN105073197A (zh) 2015-11-18
CL2015001124A1 (es) 2016-01-08
AU2018203579B2 (en) 2020-02-27
MX2020009919A (es) 2020-10-14
MX2015005555A (es) 2015-11-30
IL238564A0 (en) 2015-06-30
CA2890176C (en) 2021-12-14
KR20200136498A (ko) 2020-12-07
RS60844B1 (sr) 2020-10-30
AU2020203417A1 (en) 2020-06-11
CN105073197B (zh) 2019-06-28
US9694071B2 (en) 2017-07-04
SI3150256T1 (sl) 2021-03-31
EP3150256A1 (en) 2017-04-05
SG11201503393SA (en) 2015-06-29
KR102341275B1 (ko) 2021-12-21
EP3150256B1 (en) 2020-07-15
AU2018203579A1 (en) 2018-06-14
CY1123938T1 (el) 2022-03-24
KR20150084885A (ko) 2015-07-22
WO2014071125A1 (en) 2014-05-08
BR112015009879A8 (pt) 2019-09-17
US20150290317A1 (en) 2015-10-15
AU2013337733B2 (en) 2018-03-08
NZ708249A (en) 2019-03-29
US10729768B2 (en) 2020-08-04
SG10201704511RA (en) 2017-07-28
AU2013337733A1 (en) 2015-06-04
MX375325B (es) 2025-03-06
CA2890176A1 (en) 2014-05-08
DK3150256T3 (da) 2020-08-24
KR102185175B1 (ko) 2020-12-02
JP2016505515A (ja) 2016-02-25
PL3150256T3 (pl) 2021-02-08
EP2914343A1 (en) 2015-09-09
SMT202000543T1 (it) 2020-11-10
LT3150256T (lt) 2020-11-10
JP6437441B2 (ja) 2018-12-12
CN110269941A (zh) 2019-09-24

Similar Documents

Publication Publication Date Title
EA030745B1 (ru) Комбинация анти-cd20 антитела и селективного ингибитора киназы pi3
JP7663514B2 (ja) Ｍｃｌ－１阻害剤抗体－薬物コンジュゲートおよび使用方法
KR101968499B1 (ko) 암의 치료 및/또는 예방용 의약 조성물
US20180305449A1 (en) VEGF/DLL4 Binding Agents and Uses Thereof
EA030182B1 (ru) Антитела, специфические для кадгерина-17
WO2019046338A1 (en) ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE
US20160319034A1 (en) Met-binding agents and uses thereof
CN116284054B (zh) 一种海鞘素类化合物、其抗体药物偶联物及其应用
TW202348252A (zh) 用治療性結合分子治療癌症的組合療法
JP2022514832A (ja) 抗ｔｉｍ－３抗体とその利用
JP2024545138A (ja) 親和性が改善された抗体薬物複合体、その調製法、及びその応用
ES2813343T3 (es) Combinación de anticuerpo anti-CD20 e inhibidor selectivo de PI3 quinasa
HK40043941A (en) Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
EP4610267A1 (en) Cyclic dinucleotides and conjugates thereof with antibodies
HK1231798A1 (en) Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
HK1231798B (en) Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
EP4626553A2 (en) Tlr7 agonists and antibody-drug-conjugates thereof